Hbm Holdings Ltd vs Vertex Pharmaceuticals: Fair Value & Quality
Both stocks run through our valuation models. Here is how Hbm Holdings Ltd (2142) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 20, 2026.
As of Aug 20, 2026, Fair Value Calculator sees Hbm Holdings Ltd as the less overvalued of the two: Hbm Holdings Ltd trades at HK$14.49 versus a fair value of HK$11.32 (-22%), while Vertex Pharmaceuticals trades at $552 versus $279 (-50%).
Hbm Holdings Ltd
2142.HK · HKD · Health Care
-22%
upside to fair value
overvalued
PriceHK$14.49
Fair ValueHK$11.32
Quality73/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-50%
upside to fair value
overvalued
Price$552
Fair Value$279
Quality79/100
Get comparisons like this free by email every month: the most undervalued quality stocks.
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Hbm Holdings LtdVertex Pharmaceuticals
Valuation
11.5×P/E (TTM)28.8×
7.27×P/S (TTM)10.06×
3.13×P/B6.59×
9.4×EV/EBITDA23.8×
—PEG1.72×
—Dividend yield0.1%
Profitability
58%Net margin36%
22%Operating margin38%
38%Return on equity24%
14%Return on assets12%
Growth
294%Revenue growth (YoY)8%
57.3%Avg. growth/yr (3Y)10.6%
62.2%Avg. growth/yr (5Y)14.2%
Balance & size
0.05×Debt / equity0.03×
$1BMarket cap$123B
mixedGrowth qualityhealthy
Hbm Holdings Ltd leads: 10 to 2 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Hbm Holdings Ltdof which business quality 72 · market factors 53Vertex Pharmaceuticalsof which business quality 77 · market factors 79
ProfitabilityMargins and returns on capital today
71
72
Quality GrowthAre margins and returns improving?
100
65
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
23
58
Low VolatilityCalm price path (market factor)
19
85
MomentumPrice trend over the last 3–12 months (market factor)
64
69
52W MomentumDistance to the 52-week high (market factor)
72
90
Net IssuanceBuybacks instead of dilution
38
82
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Hbm Holdings Ltd
DCF ModelsHK$2.79
Earnings-BasedHK$3.83
MultiplesHK$1.86
Asset-BasedHK$0.29
Growth DCFHK$2.27
Economic ProfitHK$1.18
Growth EarningsHK$5.09
24 of 24 models see the stock below the current price.
Vertex Pharmaceuticals
DCF Models$453
Earnings-Based$516
Dividend Discount$7.07
Multiples$278
Asset-Based$49.27
Growth DCF$348
Economic Profit$254
Growth Earnings$692
22 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Hbm Holdings Ltd
Bear HK$8.98Fair Value HK$11.32Bull HK$14.06
HK$14.49 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$552 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Hbm Holdings Ltd · Health Care
Quality score73 · Top 25%
Fair value upside-22% · above median
Vertex Pharmaceuticals · Health Care
Quality score79 · Top 25%
Fair value upside-50% · below median
Bottom line
As of Aug 20, 2026, Fair Value Calculator sees Hbm Holdings Ltd as the less overvalued of the two: Hbm Holdings Ltd trades at HK$14.49 versus a fair value of HK$11.32 (-22%), while Vertex Pharmaceuticals trades at $552 versus $279 (-50%).
Vertex Pharmaceuticals has the higher quality score (79/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
